I Hate Dialysis Message Board
Welcome, Guest. Please login or register.
November 24, 2024, 09:16:00 PM

Login with username, password and session length
Search:     Advanced search
532606 Posts in 33561 Topics by 12678 Members
Latest Member: astrobridge
* Home Help Search Login Register
+  I Hate Dialysis Message Board
|-+  Dialysis Discussion
| |-+  Dialysis: News Articles
| | |-+  Medicare kidney dialysis guidelines finalized
0 Members and 1 Guest are viewing this topic. « previous next »
Pages: [1] Go Down Print
Author Topic: Medicare kidney dialysis guidelines finalized  (Read 1373 times)
okarol
Administrator
Member for Life
*****
Offline Offline

Gender: Female
Posts: 100933


Photo is Jenna - after Disneyland - 1988

WWW
« on: April 04, 2008, 10:07:33 AM »

Medicare kidney dialysis guidelines finalized

Thu Apr 3, 6:58 PM ET

The U.S. Centers for Medicaid & Medicaid Services said on Thursday that it has finalized coverage guidelines for patients undergoing kidney dialysis that do not include changes in anemia treatment.

The agency last year set restrictions on the use of anemia drugs for cancer patients that led to sharp declines in sales for drugmakers Amgen Inc and Johnson & Johnson.

The revised dialysis regulations mainly address issues of patient rights, patient safety and the patient's participation in the care process. The agency said in a statement that the regulation also gives dialysis centers more flexibility in the use of resources.

"We believe that with this CMS ruling Amgen avoided another potentially negative event, and we are leaving our Epogen estimates unchanged at this time," UBS analyst Maged Shenouda said in a research note on Thursday. The analyst forecast Epogen sales of $2.4 billion in 2008, growing to $2.6 billion in 2011.

Amgen's Epogen is used to treat anemia in patients undergoing kidney dialysis, while the company's Aranesp is used in patients with kidney disease and cancer patients undergoing chemotherapy. Under a license from Amgen, J&J sells Procrit for treating cancer patients. The drugs are genetically engineered versions of a protein that boosts production of oxygen-carrying red blood cells.

The Medicare agency last year sharply restricted reimbursement for anemia drugs used to treat certain cancer patients, citing studies which cast doubt on the drugs' safety.

Advisors to the U.S. Food and Drug Administration last month recommended that use of the drugs be tightened, but said the medicines should remain on the market for most cancer patients.

The drugs are one of the biggest prescription costs for Medicare, the U.S. insurance plan for about 43 million elderly and disabled. Worldwide sales of Amgen's Aranesp fell 12 percent to $3.6 billion in 2007 compared with 2006, while sales of Procrit fell 9.4 percent to $2.9 billion over the same period.

http://news.yahoo.com/s/nm/20080403/hl_nm/amgen_medicare_dc_2
Logged


Admin for IHateDialysis 2008 - 2014, retired.
Jenna is our daughter, bad bladder damaged her kidneys.
Was on in-center hemodialysis 2003-2007.
7 yr transplant lost due to rejection.
She did PD Sept. 2013 - July 2017
Found a swap living donor using social media, friends, family.
New kidney in a paired donation swap July 26, 2017.
Her story ---> https://www.facebook.com/WantedKidneyDonor
Please watch her video: http://youtu.be/D9ZuVJ_s80Y
Living Donors Rock! http://www.livingdonorsonline.org -
News video: http://www.youtube.com/watch?v=J-7KvgQDWpU
Pages: [1] Go Up Print 
« previous next »
 

Powered by MySQL Powered by PHP SMF 2.0.17 | SMF © 2019, Simple Machines | Terms and Policies Valid XHTML 1.0! Valid CSS!